- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-6148
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A feline case of multiple myeloma treated with bortezomib ; volume:18 ; number:1 ; day:3 ; month:11 ; year:2022 ; pages:1-6 ; date:12.2022
BMC veterinary research ; 18, Heft 1 (3.11.2022), 1-6, 12.2022
- Urheber
-
Tani, Hiroyuki
Miyamoto, Ryo
Miyazaki, Teruki
Oniki, Shingo
Tamura, Kyoichi
Bonkobara, Makoto
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12917-022-03484-1
- URN
-
urn:nbn:de:101:1-2023011820590909671481
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tani, Hiroyuki
- Miyamoto, Ryo
- Miyazaki, Teruki
- Oniki, Shingo
- Tamura, Kyoichi
- Bonkobara, Makoto
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
Immune-mediated neuropathy related to bortezomib in a patient with multiple myeloma
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis